LIVIVO - Search results -

Search results

Result 1 - 10 of total 431

Search options

Book: Functional reconstructive nasal surgery

Huizing, Egbert H. / Groot, John A. M. de

2015

Author's details	Egbert H. Huizing ; John A. M. de Groot
Keywords	Rhinoplasty / methods ; Reconstructive Surgical Procedures ; Nose / surgery ; Recovery of Function ; Nasenchirurgie ; Operationstechnik
Subject	Operative Technik ; Chirurgisches Verfahren ; Operationsverfahren ; Nase
Language	English
Size	XII, 413 S. : zahlr. Ill., graph. Darst.
Edition	2. ed.
Publisher	Thieme
Publishing place	Stuttgart u.a.
Publishing country	Germany
Document type	Book
HBZ-ID	HT018614479
ISBN	978-3-13-129412-8 ; 3-13-129412-4 ; 9783131641229 ; 3131641223
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2015 A 1434	available for loan (reading room)	Lesesaal EG

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer.

Panday, V R / Huizing, M T / van Warmerdam, L J / Dubbelman, R C / Mandjes, I / Schellens, J H / Huinink, W W / Beijnen, J H

Pharmacological research

1998 Volume 38, Issue 3, Page(s) 231–236

Abstract: ... pharmacokinetic data of 135 mg m-2 paclitaxel administered by 3-h infusion are scarce and fragmented, we now ... function. The administration of 135 mg m-2 single-paclitaxel was safe, and the toxicities observed ... paclitaxel dose of 135 mg m-2 given by a 3-h infusion is expected to be used more frequently in combination ...

Abstract	Paclitaxel (Taxol(R)) is an active agent in platinum-refractory ovarian cancer. Since the available pharmacokinetic data of 135 mg m-2 paclitaxel administered by 3-h infusion are scarce and fragmented, we now describe a comprehensive pharmacologic study in a group of 13 patients who were pretreated with platinum for advanced ovarian cancer. The mean paclitaxel AUC was 10.3+/-2.4 h micromol l-1 (range 6.8-13.9 h micromol l-1). Quantification of the two major paclitaxel metabolites, 6alpha-hydroxypaclitaxel and 3'-p-hydroxypaclitaxel yielded AUCs of 0.44+/-0.30 h micromol l-1 and 0.31+/-0.20 h micromol l-1, respectively. The AUC of 3'-p-hydroxypaclitaxel was significantly different from that of patients with an altered hepatic function. The administration of 135 mg m-2 single-paclitaxel was safe, and the toxicities observed at higher doses in earlier studies were absent in this study. This is important, because the schedule and paclitaxel dose of 135 mg m-2 given by a 3-h infusion is expected to be used more frequently in combination with other cytotoxic agents with the aim of improving efficacy.
MeSH term(s)	Adult ; Aged ; Antineoplastic Agents, Phytogenic/administration & dosage ; Female ; Humans ; Middle Aged ; Organoplatinum Compounds/therapeutic use ; Ovarian Neoplasms/drug therapy ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Paclitaxel/pharmacokinetics
Chemical Substances	Antineoplastic Agents, Phytogenic ; Organoplatinum Compounds ; Paclitaxel (P88XT4IS4D)
Language	English
Publishing date	1998-09
Publishing country	Netherlands
Document type	Clinical Trial ; Journal Article ; Multicenter Study ; Randomized Controlled Trial
ZDB-ID	1003347-6
ISSN	1096-1186 ; 1043-6618 ; 0031-6989
ISSN (online)	1096-1186
ISSN	1043-6618 ; 0031-6989
DOI	10.1006/phrs.1998.0360
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 721: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Book ; Thesis: Mitochondrial transmembrane carriers in mitochondriocytopathies

Huizing, Marjan

1998

Author's details	door Marjan Huizing
Language	English
Size	143 S. : Ill., graph. Darst.
Publishing country	Netherlands
Document type	Book ; Thesis
Thesis / German Habilitation thesis	Nijmegen, Kath. Univ., Diss., 1998
Note	Zsfassung in niederländ. Sprache
HBZ-ID	HT008401322
ISBN	90-901-1340-1 ; 978-90-901-1340-1
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
98 E 635	order for loan	Magazin

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Validation of liquid biopsy for ESR1-mutation analysis in hormone-sensitive breast cancer: a pooled meta-analysis.

Najim, Omar / Papadimitriou, Konstantinos / Broeckx, Glenn / Huizing, Manon / Tjalma, Wiebren

Frontiers in oncology

2023 Volume 13, Page(s) 1221773

Abstract: Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid ... ...

Abstract	Several retrospective and prospective studies have shown that genomic alterations in Estrogen-receptor one (ESR1) can be characterized not only in tissue samples but also by sequencing circulating tumor DNA (ctDNA) in liquid biopsy. Therefore, liquid biopsy is a potential noninvasive surrogate for tissue biopsy. This meta-analysis was designed to compare the prevalence of ESR 1 mutation detected with liquid biopsy and tissue biopsy. A pooled meta-analysis of studies published between 1 January 2007 and 1 March 2021 was conducted regarding the methodologies used for ESR1 mutation analysis. Liquid biopsy is a valid, inexpensive, and attractive noninvasive alternative to tumor biopsies for the identification of ESR1 mutations. Liquid biopsy for ESR 1 analysis would facilitate regular testing, allowing monitoring of the sensitivity to ET and guiding treatment strategies.
Language	English
Publishing date	2023-08-22
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2023.1221773
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Inherited disorders of lysosomal membrane transporters.

Huizing, Marjan / Gahl, William A

Biochimica et biophysica acta. Biomembranes

2020 Volume 1862, Issue 12, Page(s) 183336

Abstract: Disorders caused by defects in lysosomal membrane transporters form a distinct subgroup of lysosomal storage disorders (LSDs). To date, defects in only 10 lysosomal membrane transporters have been associated with inherited disorders. The clinical ... ...

Abstract	Disorders caused by defects in lysosomal membrane transporters form a distinct subgroup of lysosomal storage disorders (LSDs). To date, defects in only 10 lysosomal membrane transporters have been associated with inherited disorders. The clinical presentations of these diseases resemble the phenotypes of other LSDs; they are heterogeneous and often present in children with neurodegenerative manifestations. However, for pathomechanistic and therapeutic studies, lysosomal membrane transport defects should be distinguished from LSDs caused by defective hydrolytic enzymes. The involved proteins differ in function, localization, and lysosomal targeting, and the diseases themselves differ in their stored material and therapeutic approaches. We provide an overview of the small group of disorders of lysosomal membrane transporters, emphasizing discovery, pathomechanism, clinical features, diagnostic methods and therapeutic aspects. We discuss common aspects of lysosomal membrane transporter defects that can provide the basis for preclinical research into these disorders.
MeSH term(s)	Amino Acid Transport Systems, Neutral/genetics ; Amino Acid Transport Systems, Neutral/metabolism ; Cystinosis/genetics ; Cystinosis/pathology ; Histiocytosis/genetics ; Histiocytosis/pathology ; Humans ; Lysosomal Storage Diseases/genetics ; Lysosomal Storage Diseases/pathology ; Lysosomes/metabolism ; Membrane Transport Proteins/genetics ; Membrane Transport Proteins/metabolism ; Nucleoside Transport Proteins/genetics ; Nucleoside Transport Proteins/metabolism ; Organic Anion Transporters/genetics ; Organic Anion Transporters/metabolism ; Sialic Acid Storage Disease/genetics ; Sialic Acid Storage Disease/pathology ; Symporters/genetics ; Symporters/metabolism
Chemical Substances	Amino Acid Transport Systems, Neutral ; CTNS protein, human ; Membrane Transport Proteins ; Nucleoside Transport Proteins ; Organic Anion Transporters ; SLC29A3 protein, human ; Symporters ; sialic acid transport proteins
Language	English
Publishing date	2020-05-08
Publishing country	Netherlands
Document type	Journal Article ; Research Support, N.I.H., Intramural ; Review
ZDB-ID	60-7
ISSN	1879-2642 ; 1879-2596 ; 1879-260X ; 1872-8006 ; 1879-2618 ; 1879-2650 ; 0006-3002 ; 0005-2728 ; 0005-2736 ; 0304-4165 ; 0167-4838 ; 1388-1981 ; 0167-4889 ; 0167-4781 ; 0304-419X ; 1570-9639 ; 0925-4439 ; 1874-9399
ISSN (online)	1879-2642 ; 1879-2596 ; 1879-260X ; 1872-8006 ; 1879-2618 ; 1879-2650
ISSN	0006-3002 ; 0005-2728 ; 0005-2736 ; 0304-4165 ; 0167-4838 ; 1388-1981 ; 0167-4889 ; 0167-4781 ; 0304-419X ; 1570-9639 ; 0925-4439 ; 1874-9399
DOI	10.1016/j.bbamem.2020.183336
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uc I Zs.247: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Extravasation After [ 177 Lu]Lu-HA-DOTATATE Therapy.

de Vries-Huizing, Daphne M V / Cheung, Zing J / Hendrikx, Jeroen J M A / Donswijk, Maarten L / Versleijen, Michelle W J

Clinical nuclear medicine

2024 Volume 49, Issue 5, Page(s) 454–456

Abstract: Abstract: Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who was referred for peptide ... ...

Abstract	Abstract: Extravasation of the radiopharmaceutical during peptide receptor radionuclide therapy infusion is an unwanted infrequently reported event. We present the case of a 74-year old woman with a neuroendocrine tumor who was referred for peptide receptor radionuclide therapy. During intravenous infusion of 7.4 GBq [ 177 Lu]Lu-HA-DOTATATE in the upper right arm, extravasation of the radiopharmaceutical occurred through a displaced intravenous catheter. Planar scintigraphy showed pooling of radioactivity in the right upper arm. After 24 hours, the swelling in the arm was decreased; however, erythema was increased. One week later, symptoms had disappeared, and the patient did not experience any complications during follow-up of 11 months.
MeSH term(s)	Female ; Humans ; Aged ; Radiopharmaceuticals ; Octreotide/adverse effects ; Radioisotopes ; Neuroendocrine Tumors/diagnostic imaging ; Neuroendocrine Tumors/radiotherapy ; Receptors, Peptide ; Organometallic Compounds/adverse effects ; Lutetium ; Radionuclide Imaging ; Positron-Emission Tomography
Chemical Substances	copper dotatate CU-64 ; Radiopharmaceuticals ; Octreotide (RWM8CCW8GP) ; Lutetium-177 (BRH40Y9V1Q) ; Radioisotopes ; Receptors, Peptide ; Organometallic Compounds ; Lutetium (5H0DOZ21UJ)
Language	English
Publishing date	2024-03-06
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	197628-x
ISSN	1536-0229 ; 0363-9762
ISSN (online)	1536-0229
ISSN	0363-9762
DOI	10.1097/RLU.0000000000005137
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1276: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Topical Application of Deglycating Enzymes as an Alternative Non-Invasive Treatment for Presbyopia.

Delanghe, Joris R / Beeckman, Jeroen / Beerens, Koen / Himpe, Jonas / Bostan, Nezahat / Speeckaert, Marijn M / Notebaert, Margo / Huizing, Manon / Van Aken, Elisabeth

International journal of molecular sciences

2023 Volume 24, Issue 8

Abstract: Presbyopia is an age-related vision disorder that is a global public health problem. Up to 85% of people aged ≥40 years develop presbyopia. In 2015, 1.8 billion people globally had presbyopia. Of those with significant near vision disabilities due to ... ...

Abstract	Presbyopia is an age-related vision disorder that is a global public health problem. Up to 85% of people aged ≥40 years develop presbyopia. In 2015, 1.8 billion people globally had presbyopia. Of those with significant near vision disabilities due to uncorrected presbyopia, 94% live in developing countries. Presbyopia is undercorrected in many countries, with reading glasses available for only 6-45% of patients living in developing countries. The high prevalence of uncorrected presbyopia in these parts of the world is due to the lack of adequate diagnosis and affordable treatment. The formation of advanced glycation end products (AGEs) is a non-enzymatic process known as the Maillard reaction. The accumulation of AGEs in the lens contributes to lens aging (leading to presbyopia and cataract formation). Non-enzymatic lens protein glycation induces the gradual accumulation of AGEs in aging lenses. AGE-reducing compounds may be effective at preventing and treating AGE-related processes. Fructosyl-amino acid oxidase (FAOD) is active on both fructosyl lysine and fructosyl valine. As the crosslinks encountered in presbyopia are mainly non-disulfide bridges, and based on the positive results of deglycating enzymes in cataracts (another disease caused by glycation of lens proteins), we studied the ex vivo effects of topical FAOD treatment on the power of human lenses as a new potential non-invasive treatment for presbyopia. This study demonstrated that topical FAOD treatment resulted in an increase in lens power, which is approximately equivalent to the correction obtained by most reading glasses. The best results were obtained for the newer lenses. Simultaneously, a decrease in lens opacity was observed, which improved lens quality. We also demonstrated that topical FAOD treatment results in a breakdown of AGEs, as evidenced by gel permeation chromatography and a marked reduction in autofluorescence. This study demonstrated the therapeutic potential of topical FAOD treatment in presbyopia.
MeSH term(s)	Humans ; Presbyopia/drug therapy ; Aging ; Cataract/drug therapy ; Lens, Crystalline ; Glycation End Products, Advanced
Chemical Substances	Glycation End Products, Advanced
Language	English
Publishing date	2023-04-16
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms24087343
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The cycle effect quantified: reduced tumour uptake in subsequent cycles of [

Siebinga, H / Hendrikx, J J M A / de Vries-Huizing, D M V / Huitema, A D R / de Wit-van der Veen, B J

European journal of nuclear medicine and molecular imaging

2023 Volume 51, Issue 3, Page(s) 820–827

Abstract: Background: Clear evidence regarding the effect of reduced tumour accumulation in later peptide receptor radionuclide therapy (PRRT) cycles is lacking. Therefore, we aimed to quantify potential cycle effects for patients treated with [: Methods: A ... ...

Abstract	Background: Clear evidence regarding the effect of reduced tumour accumulation in later peptide receptor radionuclide therapy (PRRT) cycles is lacking. Therefore, we aimed to quantify potential cycle effects for patients treated with [ Methods: A population PK model was developed using imaging data from 48 patients who received multiple cycles of [ Results: The final PK model adequately captured observed radioactivity accumulation in kidney, spleen and tumour. A higher tumour volume was identified to increase the tumour uptake rate, where a twofold increase in tumour volume resulted in a 2.3-fold higher uptake rate. Also, continued use of long-acting SSAs significantly reduced the spleen uptake rate (68.4% uptake compared to SSA withdrawal (10.5% RSE)). Lastly, a cycle effect was significantly identified, where tumour uptake rate decreased to 86.9% (5.3% RSE) in the second cycle and even further to 79.7% (5.6% RSE) and 77.6% (6.2% RSE) in the third and fourth cycle, respectively, compared to cycle one. Conclusions: Using a population PK modelling approach, the cycle effect of reduced tumour uptake in subsequent PRRT cycles was quantified. Our findings implied that downregulation of target receptors is probably not the major cause of the cycle effect, due to a plateau in the decrease of tumour uptake in the fourth cycle.
MeSH term(s)	Humans ; Octreotide ; Neuroendocrine Tumors/radiotherapy ; Neuroendocrine Tumors/pathology ; Somatostatin ; Radioisotopes ; Receptors, Peptide ; Organometallic Compounds/therapeutic use ; Radionuclide Imaging ; Positron-Emission Tomography
Chemical Substances	copper dotatate CU-64 ; Octreotide (RWM8CCW8GP) ; Somatostatin (51110-01-1) ; Radioisotopes ; Receptors, Peptide ; Organometallic Compounds
Language	English
Publishing date	2023-10-16
Publishing country	Germany
Document type	Journal Article
ZDB-ID	8236-3
ISSN	1619-7089 ; 0340-6997 ; 1619-7070
ISSN (online)	1619-7089
ISSN	0340-6997 ; 1619-7070
DOI	10.1007/s00259-023-06463-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1227: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Postprocedural Management in Patients After Percutaneous Deep Venous Arterialization: An Expert Opinion.

Huizing, Eline / Schreve, Michiel A / Kum, Steven / de Borst, Gert J / de Vries, Jean-Paul P M / Ünlü, Çağdaş

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists

2023 , Page(s) 15266028231158946

Abstract: Clinical impact: After percutaneous deep venous arterialization (pDVA), the created arteriovenous circuit needs time to develop. Postprocedural care in patients after pDVA is essential in order to create optimal conditions for maturation of the circuit, ...

Abstract	Clinical impact: After percutaneous deep venous arterialization (pDVA), the created arteriovenous circuit needs time to develop. Postprocedural care in patients after pDVA is essential in order to create optimal conditions for maturation of the circuit, and thus save the limb. However, current literature mainly focusses on the procedure itself, making postprocedural care an underexposed topic. Therefore, this study presents an overview of the available literature of postprocedural care of pDVA patients and provides recommendations based on expert opinion when current knowledge is limited.
Language	English
Publishing date	2023-03-10
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2006618-1
ISSN	1545-1550 ; 1526-6028
ISSN (online)	1545-1550
ISSN	1526-6028
DOI	10.1177/15266028231158946
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4547: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Quantification of biochemical PSA dynamics after radioligand therapy with [

Siebinga, Hinke / de Wit-van der Veen, Berlinda J / de Vries-Huizing, Daphne M V / Vogel, Wouter V / Hendrikx, Jeroen J M A / Huitema, Alwin D R

EJNMMI physics

2024 Volume 11, Issue 1, Page(s) 39

Abstract: Background: There is an unmet need for prediction of treatment outcome or patient selection for [: Methods: A population PK model was developed using quantitative SPECT/CT data (406 scans) of 76 patients who received multiple cycles [: Results: ... ...

Abstract	Background: There is an unmet need for prediction of treatment outcome or patient selection for [ Methods: A population PK model was developed using quantitative SPECT/CT data (406 scans) of 76 patients who received multiple cycles [ Results: The population PK model adequately described observed data in all compartments (based on visual inspection of goodness-of-fit plots) with adequate precision of parameters estimates (< 36.1% relative standard error (RSE)). A significant declining uptake in tumors (k Conclusions: Our population PK model accurately described observed [
Language	English
Publishing date	2024-04-24
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2768912-8
ISSN	2197-7364
ISSN	2197-7364
DOI	10.1186/s40658-024-00642-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito